Markets
Charles Liang, CEO of Super Micro at a keynote
Charles Liang, CEO of Super Micro at a keynote (Walid Berrazeg/Getty Images)

Super Micro’s massive sales miss is the latest headache for the volatile AI trade

Super Micro erased all of its gains on the year after whiffing on earnings.

Luke Kawa
4/30/25 10:14AM

The “will he/won’t he” of tariffs has understandably become the crucial linchpin upon which stock markets turn as of late. But cracks in the AI momentum trade preceded the top in US stock markets, and were the bleeding edge and proximate cause of weakness in the S&P 500 that preceded the Rose Garden reciprocal tariffs announcement.

Hence why the ramifications of Super Micro Computer’s brutal preliminary Q3 earnings results could prove a broader challenge for the stock market as a whole. For the first three months of the year, the AI server company missed its own revenue guidance by nearly a billion as sales of about $4.55 billion were 15% shy of consensus, to boot. Adjusted earnings of roughly $0.30 also fell far short of the anticipated $0.53.

“During Q3 some delayed customer platform decisions moved sales into Q4,” the press release from Super Micro reads.

As its management team was intently focused on hitching its wagon to the rollout of Nvidia’s Blackwell GPU, the chip designer is squarely in line for some guilt by association.

“The company blamed the underperformance on customer-delivery timing, and given its increased inventory of older-generation GPUs, we believe customers will delay their rollout in favor of Nvidia’s Blackwell,” wrote Bloomberg Intelligence senior technology analyst Woo Jin Ho, who added that the big miss was “indicative of a reliance on mega-AI deals.”

The hope, of course, is that this is just demand delayed rather than demand that’s disappearing, and that it’s a company-specific problem rather than industry-wide. But shares of Nvidia are off about 2.5% in early trading, with fellow server seller Dell down 4%, suggesting some skittishness about what this means for AI-linked names as a whole.

Until this point, Super Micro had been doing quite fairly well year to date, buoyed by filing the necessary paperwork to stay on the Nasdaq and an aggressive sales growth forecast. That gave it the surface-level appearance of being a rare AI stock that was cheaply valued. This morning’s retreat erases all of its gains for the year.

To be attractive as a relatively inexpensive stock, investors need to have confidence that you can meet your operational goals. Super Micro’s massive miss, coupled with its history of accounting issues, are going to deteriorate faith in the company at best — and at worst, create another big stumbling block for an AI trade that’s already had to grapple with DeepSeek, concerns about data center demand, and tariffs before going into sharp recovery mode over the past few weeks.

More Markets

See all Markets
markets

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.